Developments HalioDx to generate tumor immune contexture data for ImCheck Phase 1/2 trial HalioDx, a closely-held immuno-oncology diagnostic company, signed a collaboration with ImCheck Therapeutics to generate tumor immune contexture information for patients enrolled in EVICTION, the first-in-human clinical... May 19, 2020